IGM Biosciences, Inc.
IGMS
$1.25
$0.054.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.36% | 25.77% | 57.64% | 74.00% | 32.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.36% | 25.77% | 57.64% | 74.00% | 32.31% |
| Cost of Revenue | -36.12% | -27.49% | -10.73% | -3.47% | 7.96% |
| Gross Profit | 36.78% | 28.02% | 11.34% | 4.12% | -7.76% |
| SG&A Expenses | -11.32% | -16.55% | 2.63% | -10.13% | -4.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.48% | -25.41% | -8.12% | -4.81% | 5.43% |
| Operating Income | 31.98% | 25.83% | 8.59% | 5.34% | -5.25% |
| Income Before Tax | 15.85% | 20.32% | 7.68% | 6.08% | -3.46% |
| Income Tax Expenses | -- | -- | -44.50% | 145.92% | 579.31% |
| Earnings from Continuing Operations | 16.06% | 20.54% | 7.74% | 5.95% | -3.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.06% | 20.54% | 7.74% | 5.95% | -3.68% |
| EBIT | 31.98% | 25.83% | 8.59% | 5.34% | -5.25% |
| EBITDA | 33.30% | 27.00% | 9.26% | 6.18% | -4.42% |
| EPS Basic | 24.10% | 32.81% | 26.89% | 30.22% | 16.68% |
| Normalized Basic EPS | 35.79% | 36.03% | 28.29% | 31.62% | 18.44% |
| EPS Diluted | 24.10% | 32.81% | 26.89% | 30.22% | 16.68% |
| Normalized Diluted EPS | 35.79% | 36.03% | 28.29% | 31.62% | 18.44% |
| Average Basic Shares Outstanding | 8.22% | 15.82% | 24.62% | 34.91% | 27.16% |
| Average Diluted Shares Outstanding | 8.22% | 15.82% | 24.62% | 34.91% | 27.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |